These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 32981127)

  • 21. Exposure Concentrations of Infants Breastfed by Women Receiving Biologic Therapies for Inflammatory Bowel Diseases and Effects of Breastfeeding on Infections and Development.
    Matro R; Martin CF; Wolf D; Shah SA; Mahadevan U
    Gastroenterology; 2018 Sep; 155(3):696-704. PubMed ID: 29857090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation.
    Duricova D; Dvorakova E; Hradsky O; Mitrova K; Durilova M; Kozeluhova J; Kohout P; Zarubova K; Bronsky J; Hradska N; Bronska E; Adamcova M; Machkova N; Hruba V; Bortlik M; Lukas M; Malickova K; Lukas M
    Inflamm Bowel Dis; 2019 Mar; 25(4):789-796. PubMed ID: 30239799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy.
    Ghalandari N; Kemper E; Crijns IH; Wolbink G; Rispens T; Smeele HT; Dolhain RJ
    Ann Rheum Dis; 2022 Mar; 81(3):402-405. PubMed ID: 34493490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease.
    Bodini G; Demarzo MG; Saracco M; Coppo C; De Maria C; Baldissarro I; Savarino E; Savarino V; Giannini EG
    Scand J Gastroenterol; 2019 Oct; 54(10):1220-1225. PubMed ID: 31553630
    [No Abstract]   [Full Text] [Related]  

  • 25. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy.
    Picardo S; Seow CH
    Drugs; 2019 Jul; 79(10):1053-1063. PubMed ID: 31183768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.
    Tse CS; Loftus EV; Raffals LE; Gossard AA; Lightner AL
    Aliment Pharmacol Ther; 2018 Jul; 48(2):190-195. PubMed ID: 29808485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
    Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
    Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
    Strik AS; van den Brink GR; Ponsioen C; Mathot R; Löwenberg M; D'Haens GR
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1128-1134. PubMed ID: 28230306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study.
    Julsgaard M; Baumgart DC; Baunwall SMD; Hansen MM; Grosen A; Bibby BM; Uldbjerg N; Kjeldsen J; Sørensen HG; Larsen L; Wildt S; Weimers P; Haderslev KV; Vind I; Svenningsen L; Brynskov J; Lyhne S; Vestergaard T; Hvas CL; Kelsen J;
    Aliment Pharmacol Ther; 2021 Nov; 54(10):1320-1329. PubMed ID: 34472644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION).
    Luu M; Benzenine E; Doret M; Michiels C; Barkun A; Degand T; Quantin C; Bardou M
    Am J Gastroenterol; 2018 Nov; 113(11):1669-1677. PubMed ID: 29961771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of Maternal Peripartum Anti-TNFα Use on Infant Immune Response.
    Sheibani S; Cohen R; Kane S; Dubinsky M; Church JA; Mahadevan U
    Dig Dis Sci; 2016 Jun; 61(6):1622-7. PubMed ID: 26725061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
    Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
    Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Narrative Review on Anti-Tumor Necrosis Factor α Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact.
    Roseira J; Ramos J
    Acta Med Port; 2019 Apr; 32(4):305-312. PubMed ID: 31067425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero.
    Prentice R; Flanagan E; Wright EK; Gibson PR; Rosella S; Rosella O; Begun J; An YK; Lawrance IC; Kamm MA; Sparrow M; Goldberg R; Prideaux L; Vogrin S; Kiburg KV; Ross AL; Burns M; Bell SJ
    Clin Gastroenterol Hepatol; 2024 Mar; ():. PubMed ID: 38492905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease.
    Ungaro RC; Yarur A; Jossen J; Phan BL; Chefitz E; Sehgal P; Kamal K; Bruss A; Beniwal-Patel P; Fox C; Patel A; Bahur B; Jain A; Stein D; Naik S; Dubinsky MC
    J Crohns Colitis; 2019 Aug; 13(8):963-969. PubMed ID: 31087100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system.
    Wieringa JW; Driessen GJ; Van Der Woude CJ
    Expert Rev Gastroenterol Hepatol; 2018 Aug; 12(8):811-818. PubMed ID: 29972674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study.
    Mitrova K; Pipek B; Bortlik M; Bouchner L; Brezina J; Douda T; Drasar T; Klvana P; Kohout P; Leksa V; Minarikova P; Novotny A; Svoboda P; Skorpik J; Ulbrych J; Veinfurt M; Zborilova B; Lukas M; Duricova D;
    J Crohns Colitis; 2022 Dec; 16(12):1808-1815. PubMed ID: 35708729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease.
    Gibson DJ; Ward MG; Rentsch C; Friedman AB; Taylor KM; Sparrow MP; Gibson PR
    Aliment Pharmacol Ther; 2020 Mar; 51(6):612-628. PubMed ID: 31961001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fetal behavior and gestational serotonin reuptake inhibitor exposure: relationships between behavior, drug dosage, plasma drug level, and a measure of drug bioeffect.
    Salisbury AL; Anderson GM; Yang A; Stika CS; Rasmussen-Torvik LJ; Gollan JK; Wisner KL
    Neuropsychopharmacology; 2024 Dec; 49(13):1968-1977. PubMed ID: 39127823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.